395074-85-8

Usage

Derivative of isoquinoline

The compound is derived from isoquinoline, a heterocyclic aromatic organic compound.

Pharmaceutical use

The chemical is often used in the pharmaceutical industry as a building block for the synthesis of various drugs and pharmaceuticals.

Potential pharmacological properties

The compound has potential pharmacological properties and has been studied for its potential use in the treatment of various conditions.

Potential use in treatment of conditions

The compound has been studied for its potential use in the treatment of conditions such as inflammation and neurodegenerative disorders.

Potential anti-cancer properties

The compound has been studied for its potential anti-cancer properties.

Ongoing research and development

The compound is the subject of ongoing research and development in the field of medicinal chemistry, and may have potential therapeutic applications.

Upstream product

• 395074-84-7 isoquinolin-5-yl-acetic acid methyl ester 
• 581811-80-5 ethyl Isoquinolin-5-ylacetate 
• 34784-04-8 5-bromoisoquinoline 
• 581812-70-6 ethyl 2-hydroxy-2-(isoquinolin-5-yl)acetate 
• 581812-71-7 ethyl (Acetyloxy)(isoquinolin-5-yl)acetate 

Relevant academic research and scientific papers

Design and synthesis of a novel, orally active, brain penetrant, tri-substituted thiophene based JNK inhibitor

The SAR of a series of tri-substituted thiophene JNK3 inhibitors is described. By optimizing both the N-aryl acetamide region of the inhibitor and the 4-position of the thiophene we obtained single digit nanomolar compounds, such as 47, which demonstrated an in vivo effect on JNK activity when dosed orally in our kainic acid mouse model as measured by phospho-c-jun reduction.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Synthesis of imidazole intermediates

The invention provides a method for synthesis of compounds of formula wherein R1 and R19 are as defined. Compounds of formula 12 are useful as intermediates for synthesizing compounds having pharmacological activity inhibiting cdk5, cdk2, and GSK-3.

Imidazole derivatives

The invention provides compounds of formula 1 wherein R1, R2, R3, and R4 are as defined, and their pharmaceutically acceptable salts. Compounds of formula 1 are indicated to have activity inhibiting cdk5, cdk2, and GSK-3. Pharmaceutical compositions and methods comprising compounds of formula 1 for treating and preventing diseases and conditions comprising abnormal cell growth, such as cancer, and neurodegenerative diseases and conditions and those affected by dopamine neurotransmission. Also described are pharmaceutical compositions and methods comprising compounds of formula 1 for treating male fertility and sperm motility; diabetes mellitus; impaired glucose tolerance; metabolic syndrome or syndrome X; polycystic ovary syndrome; adipogenesis and obesity; myogenesis and frailty, for example age-related decline in physical performance; acute sarcopenia, for example muscle atrophy and/or cachexia associated with burns, bed rest, limb immobilization, or major thoracic, abdominal, and/or orthopedic surgery; sepsis; hair loss, hair thinning, and balding; and immunodeficiency.